多发性骨髓瘤抗BCMA CAR T细胞治疗后Th17.1细胞驱动的类结节病炎症
本文报告一例多发性骨髓瘤患者接受Idecabtagen Vicleucel(Ide-cel)后出现肺部炎症 flare-up 的病例研究,利用单细胞RNA测序(scRNA-seq)鉴定出Th17.1驱动的自身免疫机制为该现象的生物学基础。通过整合多种肺部病理数据集,揭示CAR T后肺部病变与结节病存在转录组相似性,并探索基于PET的无创诊断方法,显示CXCR4结合示踪剂可补充FDG PET成像,有助于区分免疫介导的改变与真正的复发。
要点
- Ide-cel治疗后肺部flare-up经scRNA-seq鉴定为Th17.1驱动的自身免疫现象。
- CAR T后肺部病变与结节病在转录组层面具有相似性。
- CXCR4结合示踪剂PET可补充FDG PET,帮助区分免疫介导改变与真性复发。
核心结论
- 本研究突出显示了CAR T后Th17.1驱动的自身免疫现象,可能被误判为疾病复发,多示踪剂PET成像和scRNA-seq有助于解决这一诊断困境。
研究设计与样本
- 病例研究,对一例接受Idecabtagen Vicleucel(Ide-cel)治疗的多发性骨髓瘤患者进行单细胞RNA测序(scRNA-seq)分析,并整合多种肺部病理数据集进行比较。
主要发现
- 通过整合多种肺部病理条件的数据集,揭示CAR T后肺部病变与结节病之间存在转录组相似性。
- 探索了基于PET的无创诊断方法,显示在该情形下与CXCR4结合的示踪剂可补充FDG PET成像,从而能够区分免疫介导的改变与CAR T细胞治疗后的真性复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present a case study on pulmonary flare-up after Idecabtagen Vicleucel (Ide-cel), a BCMA targeting CAR T-cell therapy, and used single-cell RNA-seq (scRNA-seq) to identify a Th17.1 driven autoimmune mechanism as the biological underpinning of this phenomenon. By integrating datasets of various lung pathological conditions, we revealed transcriptomic similarities between post CAR T pulmonary lesions and sarcoidosis. Furthermore, we explored a noninvasive PET based diagnostic approach and showed that tracers binding to CXCR4 complement FDG PET imaging in this setting, allowing discrimination between immune-mediated changes and true relapse after CAR T-cell treatment. In conclusion, our study highlights a Th17.1 driven autoimmune phenomenon after CAR T, which may be misinterpreted as disease relapse, and that imaging with multiple PET tracers and scRNA-seq could help in this diagnostic dilemma.
引用
- Leipold AM, Werner RA, Düll J, et al. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. Leukemia. 2023. PMID: 36720972. doi:10.1038/s41375-023-01824-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。